Skip to content
2000
Volume 2, Issue 2
  • ISSN: 1877-9123
  • E-ISSN: 1877-9131

Abstract

The applications for ocular implants are as broad as the pathology of eye. The success of treating ophthalmologic disease will be enhanced by targeted and sustained drug delivery. The eye is a privileged site and has several mechanisms that protect it from the external environment. This same machinery that guards the eye, also hinders drug delivery. Recent advances in ocular implants are adapting these devices for the treatment eye diseases ranging from glaucoma to diabetic retinopathy. Advances in biodegradable polymers enable ocular implant to have dual mode drug release profiles to simultaneously deliver a loading dose and maintenance dose. We explore patents that adapt traditional medications to these advanced drug delivery systems for the continuous treatment of glaucoma and potentially promising therapies for the sustained delivery of small RNA interfering molecules to block gene expression in the eye. We also examine several issued patents and follow the preliminary findings in clinical trials. Together, these inventions mark the frontier of novel drug delivery systems and present a promising mode to adapt current therapies to new delivery systems for the treatment of chronic ocular disease.

Loading

Article metrics loading...

/content/journals/pnm/10.2174/1877912311202020113
2012-10-01
2025-09-10
Loading full text...

Full text loading...

/content/journals/pnm/10.2174/1877912311202020113
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test